Clinical Testing News and Research

RSS

iCAD and AdMeTech Foundation sign a strategic partnership agreement

iCAD, Inc., an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announces a strategic partnership with the AdMeTech Foundation, a non-profit organization with a mission to end prostate cancer as a patient care crisis and socio-economic problem.

19 Nov 2009

Majority of mothers personally manage their children's health this coming winter

Three out of four mothers with a child between the ages of two through 12 are extremely, very, or somewhat concerned about their child's health this coming winter, according to a survey conducted by Opinion Research Corporation and commissioned by Bionorica, an international company pioneering clinical research of natural remedies including Sinupret® for Kids, a product which supports healthy respiratory function in children (www.bionoricausa.com).

18 Nov 2009

Advanced BioMedical Technologies commences animal tests with novel patented PA bio-absorbable material

Advanced BioMedical Technologies Inc. announced that the Company's subsidiary, Shenzhen Changhua Biomedical Engineering Co., Ltd., has signed a cooperative agreement with The First Affiliated Hospital of Guangdong Pharmaceutical University ("GDPU Hospital") in Guangzhou. Under this cooperative agreement, both parties will join efforts in conducting research and animal tests on Cranio-Maxillofacial Fracture Treatment and Craniofacial Reconstruction utilizing ABT-CHANGHUA's novel patented PA (Polyamide) bio-absorbable material.

17 Nov 2009

Fate Therapeutics announces the completion of $30 million Series B financing

Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor.

16 Nov 2009

Cortex Pharmaceuticals reports a net loss of $0.06 per share for the quarter ended September 30, 2009

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of $3,243,000, or $0.06 per share for the quarter ended September 30, 2009 compared with a net loss applicable to common stock of $3,148,000, or $0.07 per share for the corresponding prior year period.

16 Nov 2009

Postmortem genetic testing to identify genetic mutations after SUD effective in identifying risk

Targeted postmortem testing to identify genetic mutations associated with sudden unexplained death (SUD) is an effective and less expensive way to determine risk to relatives than comprehensive cardiac testing of first degree relatives, according to research presented at the American Heart Association's Scientific Sessions 2009.

16 Nov 2009

Adolor commences clinical testing of its oral mu opioid receptor antagonist

Adolor Corporation today announced the initiation of clinical testing of ADL7445, its proprietary, oral mu opioid receptor antagonist for the treatment of Opioid Bowel Dysfunction (OBD). The Phase 1, single ascending dose trial in healthy volunteers will assess safety and tolerability of the compound and will be followed by a multiple ascending dose study in early 2010.

13 Nov 2009

OPKO Health acquires NK-1 compounds from Schering

OPKO Health, Inc. today announced that it has completed the acquisition of rolapitant and a related compound from Schering Corporation, a subsidiary of Merck & Co., Inc. ("Schering").

11 Nov 2009

New non-invasive procedures may help in reducing localized fat safely and effectively

For many people, diet and exercise help keep them looking and feeling healthy. But even those who work hard on staying in shape might have a hard time shaking stubborn love handles or lower belly fat, which can bulge through clothing like a neon sign. While the market for getting rid of unwanted fat has grown over the years to include stomach stapling and behavioral techniques, there is still a demand for procedures that can reduce areas of localized fat safely and effectively.

11 Nov 2009

Health information technology's 11% combined annual growth rate to continue through 2013: Scientia Advisors

Health information technology (HIT) is the fastest growing segment of the $1 trillion global health care marketplace—and its “impressive” 11 per cent combined annual growth rate is likely to continue through 2013, according to a Scientia Advisors global industry review released today.

10 Nov 2009

Teva Pharmaceutical Industries amends patent infringement lawsuit against Momenta Pharmaceuticals/Sandoz

Teva Pharmaceutical Industries Ltd. announced today it is seeking to amend its existing complaint against Momenta Pharmaceuticals, Inc./Sandoz Inc. to include patent infringement of three additional patents related to the characterization of COPAXONE® (glatiramer acetate injection). The proposed updated complaint has been filed under seal with the U.S. District Court for the Southern District of New York along with a motion requesting that the Court grant Teva leave to amend.

10 Nov 2009

FDA approved stem cell therapy restores limb function in rats with neck spinal cord injuries

The first human embryonic stem cell treatment approved by the FDA for human testing has been shown to restore limb function in rats with neck spinal cord injuries - a finding that could expand the clinical trial to include people with cervical damage.

10 Nov 2009

Bioniche Life Sciences announces financial results for its Fiscal 2010 first-quarter

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 first quarter, ended September 30, 2009.

6 Nov 2009

GenVec and SAIC-Frederick signs contract to develop influenza and HIV vaccines

GenVec, Inc, announced today that SAIC-Frederick, Inc. has signed a contract with GenVec for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

5 Nov 2009

Scientists develop technique to predict new target diseases for existing drugs

Scientists at the University of North Carolina at Chapel Hill School of Medicine and the University of California, San Francisco have developed and experimentally tested a technique to predict new target diseases for existing drugs.

4 Nov 2009

Entest BioMedical and Quantum Advisors sign Letter of Intent

Entest BioMedical Inc. (OTCBB: ENTB) announced today that it has signed a Letter of Intent with Quantum Advisors, a San Diego based biotechnology consulting firm, to assist Entest with the development of its Stem Cell Therapeutic Treatment for Chronic Obstructive Pulmonary Disease (COPD).

3 Nov 2009

Fiscal 2009 results announced by Helix BioPharma

Helix BioPharma Corp. today announced financial results for the year ended July 31, 2009.

30 Oct 2009

Non-surgical alternative treatment for moderate to advanced gum disease announced

BIOLASE Technology, Inc. today announced its new Deep Pocket Therapy with New Attachment™ using the Waterlase MD™ and patented Radial Firing Perio Tips™ (RFPT) for a non-surgical alternative treatment for moderate to advanced gum disease.

29 Oct 2009

Sangamo BioSciences awarded a grant to develop zinc finger nuclease-based stem cell therapy for AIDS

Sangamo BioSciences, Inc. announced today that the California Institute for Regenerative Medicine (CIRM) has granted a $14.5 million Disease Team Research Award to develop an AIDS-related lymphoma therapy based on the application of its zinc finger nuclease (ZFN) gene-editing technology in stem cells.

29 Oct 2009

Repros Therapeutics amends its existing license for Proellex

Repros Therapeutics today announced that the Company has entered into an amendment with the National Institutes of Health (NIH) to its existing exclusive license for Proellex® that revises the existing milestones and dates for performance to provide additional time to lift the current clinical hold on Proellex or select a second generation molecule for further development from the family of anti-progestational agents covered by the license.

29 Oct 2009

Clinical Testing News and Research

iCAD and AdMeTech Foundation sign a strategic partnership agreement

Majority of mothers personally manage their children's health this coming winter

Advanced BioMedical Technologies commences animal tests with novel patented PA bio-absorbable material

Fate Therapeutics announces the completion of $30 million Series B financing

Cortex Pharmaceuticals reports a net loss of $0.06 per share for the quarter ended September 30, 2009

Postmortem genetic testing to identify genetic mutations after SUD effective in identifying risk

Adolor commences clinical testing of its oral mu opioid receptor antagonist

OPKO Health acquires NK-1 compounds from Schering

New non-invasive procedures may help in reducing localized fat safely and effectively

Health information technology's 11% combined annual growth rate to continue through 2013: Scientia Advisors

Teva Pharmaceutical Industries amends patent infringement lawsuit against Momenta Pharmaceuticals/Sandoz

FDA approved stem cell therapy restores limb function in rats with neck spinal cord injuries

Bioniche Life Sciences announces financial results for its Fiscal 2010 first-quarter

GenVec and SAIC-Frederick signs contract to develop influenza and HIV vaccines

Scientists develop technique to predict new target diseases for existing drugs

Entest BioMedical and Quantum Advisors sign Letter of Intent

Fiscal 2009 results announced by Helix BioPharma

Non-surgical alternative treatment for moderate to advanced gum disease announced

Sangamo BioSciences awarded a grant to develop zinc finger nuclease-based stem cell therapy for AIDS

Repros Therapeutics amends its existing license for Proellex

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News